Advances in Pulmonary Fibrosis
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Pathology".
Deadline for manuscript submissions: 1 December 2025 | Viewed by 1087
Special Issue Editor
Special Issue Information
Dear Colleagues,
Idiopathic pulmonary fibrosis (IPF) is a fibrosing interstitial lung disease characterized by a progressive decline in exercise capacity, difficulty breathing, recurrent infections, and a severe impairment in lung function, which makes the patients dependent on long-term oxygen treatment. Due to the lack of effective treatments, the median survival time of patients from diagnosis is 2–4 years. Currently, lung transplantation is the only therapeutic option and is carried out in fewer than 5% of IPF patients with a very severe stage of disease. Thus, there is an urgent need to identify novel mechanisms implicated in the onset and development of this disease, as well as potential therapies.
Potential topics for inclusion in this Special Issue include the following:
- Novel biomarkers;
- Experimental therapeutics;
- Animal models (cellular and molecular pathophysiology and experimental therapies);
- The identification of novel mechanisms in IPF.
Dr. Sergio Piñeiro Hermida
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pulmonary fibrosis
- animal models
- biomarkers
- experimental therapeutics
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
